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, the signaling pathways utilized by insulin to stimulate sterol regulatory element-binding protein (SREBP)-1c could remain intact in obesity and type 2 diabetes, even as the pathways that regulate glucose metabolism become resistant. These dual actions contribute to the lethal combination of hyperglycemia and hypertriglyceridemia that characterizes the diabetic state.
Increased lipogenesis observed in the insulin-resistant state is partially because of dysregulation of the master transcriptional regulator of lipogenesis, the SREBP-1c. The SREBP family consists of three isoforms: SREBP-1a, SREBP-1c and SREBP-2 2 . SREBP-1c is an isoform that controls the biosynthesis of fatty acids and triglycerides by increasing transcription of genes encoding acetyl-CoA carboxylase, fatty acid synthase, elongation of very long chain fatty acids family member 6, stearoyl-CoA desaturase and others. Insulin activates SREBP-1c through at least two mechanisms: (i) it increases SREBP-1c transcription; and (ii) it increases the proteolytic cleavage of SREBP-1c from an inactive endoplasmic reticulum membrane-bound precursor to release their N-terminal domain capable of translocating to the nucleus to activate transcription ( Figure 1 phosphatase and transcriptional coactivator, is a direct substrate of mTORC1 and regulator of nuclear SREBP activity. Lipin-1 phosphorylation by mTORC1 blocks lipin's nuclear localization and activates SREBP-1c activity. In the insulin-resistant state, insulin might continue to activate mTORC1 while losing its ability to inhibit forkhead box O1. The cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB)-regulated transcription coactivators (CRTCs) physically interact with CREB through its N-terminal portion, and coactivate the transcriptional activity of CREB through its C-terminally located transactivation domain. cAMP-dependent activation of this transcriptional machinery promotes hepatic gluconeogenic programs by upregulation of key enzyme genes, such as phosphoenolpyruvate carboxykinase and glucose-6-phosphatase catalytic subunit 3, 4 . Although the function of CRTCs in the liver has been extensively studied in the context of gluconeogenesis, Han et al. 5 recently showed that cytosolic CRTC2, as a critical mediator of mTOR, modulates coat protein complex II (COPII) activity, which subsequently leads to SREBP-1 processing and enhancement of de novo lipogenesis.
These authors measured hepatic lipid levels in Crtc2 +/+ and Crtc2 -/-mice. They found that Crtc2 -/-mice showed increased hepatic triglyceride levels, but not cholesterol, when compared with Crtc2 +/+ mice fed with both regular chow and a high-fat diet. Transcript analysis showed specific upregulation of SREBP1-target genes involved in triglyceride synthesis in the livers of Crtc2 -/-mice. In Crtc2 -/-mice fed with both chow and a high-fat diet, the active, nuclear SREBP-1 was significantly increased while the precursor, full-length SREBP-1 was slightly decreased, although total Srebp-1c mRNA levels remained unchanged. These results suggest that CRTC2 mediates SREBP-1 activity at the post-transcriptional level. In addition, the abnormal nuclear SREBP-1 accumulation and the enhanced lipogenic gene expression in Crtc2 -/-mice were normalized to the level found in fed Crtc2 +/+ mice by adenovirusmediated CRTC2 overexpression or knockdown of Srebp-1. Taken together, these results show that CRTC2 modulates triglyceride synthesis through regulation of SREBP-1 maturation.
In the liver, cAMP signaling activates CRTC2 activity through Ser171 dephosphorylation resulting in its nuclear localization and increased association with CREB on the promoters of gluconeogenic genes. Han et al. 5 examined the effects of the cellular localization of CRTC2 on SREBP1 maturation using two CRTC2 mutants: (i) DTAD (amino acids 1-630), which lacks the transactivation domain, but still shuttles between the cytoplasm and nucleus; and (ii) DTAD/AA, which is confined to the nucleus because of serine-to-alanine mutations at positions 171 and 275. Similar to wild-type CRTC2, the DTAD mutant also blocks SREBP-1 maturation in Crtc2 -/-mice, whereas DTAD/AA mutant was not able to suppress the processing of SREBP-1, suggesting that SREBP-1 processing depends on cytosolic but not nuclear CRTC2.
Using mass spectrometry and coimmunoprecipitation analysis, they found that CRTC2 binds to proteins involved in SREBP-1 transport regulation. Insulin regulates SREBP activity through stimulation of endoplasmic reticulum-to-Golgi SREBP-1c transport by promoting its phosphorylation and association with COPII vesicles. Indeed, CRTC2 binds to Sec31A, a subunit of the COPII complex, and negatively regulates SREBP-1 processing by competing with Sec23A for binding to Sec31A.
Finally, Han et al. 5 found that the CRTC2-Sec31 interactions modulate hormonal and nutritional activation of SREBP-1. Indeed, both insulin and amino acid stimulation attenuated the CRTC2-Sec31A interaction with concomitant enhancement of the Sec23A-Sec31A association. The regulatory effects of CRTC2 on the Sec23-Sec31A interaction were inhibited in the presence of torin1, an inhibitor of mTOR, which controls lipid metabolism and SREBP-1 activation. The conserved serine site at position 136 of CRTC2, which occurs in the context of a classic mTOR substrate motif (S/T-P), was phosphorylated without and dephosphorylated with rapamycin treatment. In addition, a co-immunoprecipitation assay and in vitro kinase assay showed that mTOR interacts with CRTC2, and mTOR directly phosphorylates CRTC2 at Ser136. Both insulin and amino acids stimulate CRTC2 Ser136 phosphorylation in an mTOR-dependent manner, suggesting that CRTC2 is a bona fide substrate of mTOR. Taken together, these results show that mTOR modulates COPII-dependent SREBP1 processing through Ser136 phosphorylation of CRTC2 (Figure 1 ).
The elegant study by Han et al.
5
greatly advances our understanding of the specific signaling pathways by which insulin stimulates lipogenesis, and provides new insight into how SREBP-1 activity is enhanced in obesity and type 2 diabetes. This study thus identifies mTOR-CRTC-SREBP-1 signaling as a potential therapeutic target for ameliorating hyperglycemia, hypertriglyceridemia and hepatic steatosis in type 2 diabetes. Further unveiling of the molecular mechanism(s) that regulate this signaling axis in obesity and diabetes will hopefully result in effective ways to overcome insulin resistance and provide a basis for beneficial treatment of type 2 diabetes.
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